Abstract:Introduction/objectivesThe dosing of intravenous immunoglobulin (IVIG) therapy for Kawasaki disease (KD) has been a matter of debate for decades, with recent studies implicating that larger doses lead to better outcomes. Despite this, few have investigated post-IVIG infusion immunoglobulin G (IgG) levels in relation to outcomes of KD such as response to IVIG and development of coronary artery abnormalities (CAAs). The present study investigated how varying levels of post-infusion IgG affected these outcomes.MethodWe collected demographic and laboratory data, including post-infusion IgG, from children with KD who were admitted to six hospitals in Japan between 2006 and 2012. We conducted multivariate analyses to examine the relationship between independent variables and non-response to IVIG and development of CAAs. We used random forest, a decision tree-based machine learning tool, to investigate the marginal effect of varying post-infusion IgG levels on non-response to IVIG and development of CAAs.ResultsOf 456 patients included in the study, 130 (28.5%) were non-responders and 38 (8.3%) developed CAAs. Sodium, post-infusion IgG, and AST were significantly associated with non-response. Post-infusion IgG and sodium were significantly associated with CAA development. The random forest plots revealed a decrease in non-response and CAA rates with increasing post-infusion IgG until post-infusion IgG was near the median (2821 mg/dL), after which the non-response and CAA rates leveled off.ConclusionsGreater post-infusion IgG is associated with better response to IVIG and decreased CAA development in KD patients, but this effect levels off at post-infusion IgG levels greater than the median.Key points• Though previous studies have shown that post-intravenous immunoglobulin (IVIG) infusion immunoglobulin G (IgG) is associated with non-response to IVIG therapy and coronary artery abnormality (CAA) development in Kawasaki disease (KD) patients, no study has investigated the relationship between varying levels of post-infusion IgG and these clinical outcomes.• Our study showed that non-response to IVIG therapy and CAA development in Kawasaki disease patients follow a decreasing trend with increasing post-infusion IgG at post-infusion IgG levels below the median.• At values of post-infusion IgG greater than the median, non-response and CAA development rates remain relatively constant with increasing post-infusion IgG.• Our study suggests that when post-infusion IgG is greater than the median, IgG may have fully bound to the therapeutic targets of KD, and in these patients, there may be limited benefit in administering additional IVIG.

Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms

Center of Diagnosis and Treatment of Intravenous Immunoglobulin-Refractory Kawasaki Disease

Thinking beyond intravenous immunoglobulin for Kawasaki disease

The prediction and treatment for intravenous immunoglobulin resistant Kawasaki disease

The Network of Pro-Inflammatory Factors CD147, DcR3, and IL33 in the Development of Kawasaki Disease.

Study on the Mechanism of Intravenous Immunoglobulin in Treating Kawasaki Disease

Risk Factors of Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease: A Meta-Analysis of Case-Control Studies

Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease

Clinical Analysis of Intravenous Immunoglobulin in the Patients with Kawasaki Disease

Bioinformatics identification of hub genes and signaling pathways regulated by intravenous immunoglobulin treatment in acute Kawasaki disease

Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.

Intravenous Immunoglobulin Therapy Restores the Quantity and Phenotype of Circulating Dendritic Cells and CD4+ T Cells in Children With Acute Kawasaki Disease

Electrocardiographic Changes in Acute Kawasaki Disease in the Era of Immunoglobulin Therapy

Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG

Clinical Features in Patients With Intravenous Immunoglobin Resistant Kawasaki Disease

Evaluation Of Intravenous Immunoglobulin Resistance And Coronary Artery Lesions In Relation To Th1/Th2 Cytokine Profiles In Patients With Kawasaki Disease

The mechanism of intravenous immunoglobulin (IVIG) in vascular endothelial injury in kawasaki disease based on neutrophil extracellular traps

Effect of Early Intravenous Immunoglobulin Therapy in Kawasaki Disease: A Systematic Review and Meta-Analysis

The Epidemiology and Pathogenesis of Kawasaki Disease

Kawasaki Disease and Inborn Errors of Immunity: Exploring the Link and Implications

Coronary artery complications in patients with Kawasaki disease who successfully responded to the standard initial IVIG treatment